{
    "clinical_study": {
        "@rank": "61881", 
        "arm_group": [
            {
                "arm_group_label": "TMS Therapy", 
                "arm_group_type": "Experimental", 
                "description": "TMS treatment"
            }, 
            {
                "arm_group_label": "TMS-Sham", 
                "arm_group_type": "Sham Comparator", 
                "description": "This is a sham TMS condition"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators are investigating new indications of Transcranial Magnetic Stimulation\n      (TMS) by conducting a pilot randomized-controlled trial (RCT) comparing structural\n      neuronavigation-directed TMS to Sham-TMS Placebo therapy for treatment of Generalized\n      Anxiety Disorder  (GAD)."
        }, 
        "brief_title": "Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Generalized Anxiety Disorder", 
        "condition_browse": {
            "mesh_term": "Anxiety Disorders"
        }, 
        "detailed_description": {
            "textblock": "Twenty participants (n = 10 per group) will be recruited. Participants will complete\n      structural MRI for neuronavigation. Participants will be randomly assigned to treatment\n      condition. TMS or Sham-TMS sessions will occur daily 5 days/week for 6 weeks. Assessments\n      will occur at pretreatment, weekly during treatment, post-treatment, 3 month and 6-month\n      follow-up.\n\n      5 participants who received  sham \"placebo\" TMS, and achieved <50% improvement in the HARS\n      at the 3 month follow-up will be recruited for an open label substudy.  These participants\n      will receive TMS treatment 2 days/week for 5 weeks.  Assessments will occur at pretreatment,\n      weekly during treatment, post-treatment, 3 month and 6-month follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with GAD as the principal or co-principal disorder\n\n          -  Clinical Global Impression Score \u2265 4\n\n          -  Hamilton Anxiety Rating Scale \u2265 18\n\n          -  Hamilton Rating Scale for Depression \u2264 17\n\n          -  Fluency in English\n\n          -  Capacity to understand the nature of the study and willingness to sign informed\n             consent form.\n\n        Exclusion Criteria:\n\n          -  History of epilepsy or head trauma (LOC > 5 minutes) within the past 6 months.\n\n          -  Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain\n             tumor, multiple sclerosis, or brain surgery.\n\n          -  A review of patient medications by the study physician indicates an increased risk of\n             seizure.\n\n          -  An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any\n             unstable cardiac disease; hypertension; or severe renal or liver insufficiency.\n\n          -  Substance use disorder or PTSD within the past 6 months.\n\n          -  Lifetime bipolar disorder, obsessive-compulsive disorder (OCD), psychotic disorder,\n             mental retardation, or pervasive developmental disorder.\n\n          -  Any psychotic features, including dementia or delirium. Concurrent psychotherapy and\n             unwillingness to discontinue\n\n          -  Medication change within past 3 months.\n\n          -  Current serious suicidal or homicidal ideation, and/or serious suicidal attempt\n             within past 6 months.\n\n          -  Serious, unstable, or terminal medical condition or clinically judged too\n             psychiatrically unstable to participate in the study.\n\n          -  Any contraindication for participation in MRI scan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659736", 
            "org_study_id": "DIEF003523.1"
        }, 
        "intervention": {
            "arm_group_label": [
                "TMS Therapy", 
                "TMS-Sham"
            ], 
            "description": "Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.\nTreatment in the substudy will entail 2 days/week sessions of TMS for 5 weeks.", 
            "intervention_name": "TMS", 
            "intervention_type": "Device", 
            "other_name": "Transcranial Magnetic Stimulation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "contact": {
                "email": "Gdiefen@harthosp.org", 
                "last_name": "Gretchen J Diefenbach, Ph.D.", 
                "phone": "860-545-7386"
            }, 
            "facility": {
                "address": {
                    "city": "Hartford", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06105"
                }, 
                "name": "Hartford Hospital"
            }, 
            "investigator": {
                "last_name": "Gretchen J Diefenbach, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder", 
        "overall_contact": {
            "email": "Gdiefen@harthosp.org", 
            "last_name": "Gretchen J Diefenbach, Ph.D.", 
            "phone": "860-545-7685"
        }, 
        "overall_official": {
            "affiliation": "Hartford Hospital", 
            "last_name": "Gretchen J Diefenbach, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Hamilton Anxiety Rating Scale is one of the most commonly used and extensively validated outcome measures for anxiety symptoms.  The SIGH-A allows for a standardized administration of the Hamilton Anxiety Rating Scale (HARS).  Participants will be categorized for some analyses based upon treatment remission status defined as SIGH-A score.", 
            "measure": "Change in the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A)before and after TMS treatment.", 
            "safety_issue": "No", 
            "time_frame": "Session 1 of TMS treatment, 1 week after last TMS treatment session"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659736"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hartford Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hartford Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}